MHRA Approves Serplulimab for Extensive-Stage SCLC

Small Cell Lung Cancer (SCLC): Symptoms, Causes, Diagnosis, Treatment, and Prevention

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer . The other type is non-small cell lung cancer (NSCLC). SCLC is less common than NSCLC, accounting for about 15 percent of all lung cancers.e60dc2a1-f33c-4a05-9b50-8e3e8e597629480a00b2-b9a1-469b-bee5-6a9e93e3f115 This cancer is named for the size of the cells, which look smaller under a microscope than healthy lung cells or NSCLC c…

Accord Healthcare receives approval for Hetronifly® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Intas and its subsidiary Accord Healthcare lead commercialisation in Europe and India. In December 2022, serplulimab received orphan drug designation from the...

DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Jun 23, 2025-

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC

The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.

Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS - ILCN.org (ILCN/WCLC)

New therapeutic options are desperately needed for patients with small cell lung cancer (SCLC) whose disease has progressed or who have experienced disease recurrence after first-line therapy with a platinum-based chemotherapy, as current second-line standard-of-care (SOC) chemotherapy options for these patients result in modest overall survival (OS) benefit at best. Charles M. Rudin, MD, PhD Fortunately, the novel agent tarlatamab, based on ef…

MHRA Approves Serplulimab for Extensive-Stage SCLC

The MHRA has approved serplulimab, the UK’s first anti-PD-1 antibody for extensive-stage small cell lung cancer, improving survival options for adults.